10/23/2026
For Ildikó Krencz, MD, PhD, LAM first entered her life through the laboratory.
In 2015, while beginning her PhD focused on lung neoplasms, Ildiko was also working in the laboratory of Professor Anna Sebestyén, where researchers were investigating the mTOR pathway. That same year, sirolimus was approved by the FDA to treat LAM. The connection was natural, and Ildiko soon began exploring LAM and the biology behind this rare lung disease.
What began as a research interest has grown into more than a decade of work dedicated to understanding LAM, and into a deep connection with the people who make up the LAM community.
Read more about Dr. Krencz and her career in LAM research: https://www.thelamfoundation.org/from-research-interest-to-a-decade-of-discovery-meet-ildiko-krencz/